Assigning osteoporosis treatment on the basis of bone mineral density alone is difficult, and incorporating even simple clinical risk factors into the decision-making process is challenging. When launched, the FRAX® risk assessment tool was met, unsurprisingly, with both enthusiasm and skepticism; despite improvements, some obstacles still prevent its universal implementation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kanis, J. A. et al. Interpretation and use of FRAX in clinical practice. Osteoporos. Int. 22, 2395–2411 (2011).
[No authors listed] Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. 843, 1–129 (1994).
Kanis, J. A., on behalf of the World Health Organization Scientific Group (2008). Assessment of osteoporosis at the primary healthcare level. Technical report. WHO Collaborating Centre. University of Sheffield, UK. http://www.shef.ac.uk/FRAX/ (2008).
Lyles, K. W. et al. Zoledronic acid and clinical fracture and mortality after hip fracture. N. Engl. J. Med. 357, 1799–1809 (2007).
Bolland, M. J., Grey, A. B., Gamble, G. D. & Reid, I. R. Effect of osteoporosis treatment on mortality: a meta-analysis. J. Clin. Endocrinol. Metab. 95, 1174–1181 (2010).
Marshall, D., Johnell, O. & Wedel, H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312, 1254–1259 (1996).
Abrahamsen, B. et al. Discordance between changes in bone mineral density measured at different skeletal sites in perimenopausal women—implications for assessment of bone loss and response to therapy: The Danish Osteoporosis Prevention Study. J. Bone Miner. Res. 16, 1212–1219 (2001).
Leslie, W. D. et al. Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos. Int. 22, 839–847 (2011).
Giangregorio, L. M. & Leslie, W. D. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J. Bone Miner. Res. 25, 1400–1405 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has received grant/research support from Amgen, Merck, Novartis, NPS Pharmaceuticals, and Nycomed; consulting fees from Amgen, Merck and Nycomed; and speakers bureau from Amgen, Eli Lilly, Merck and Nycomed.
Rights and permissions
About this article
Cite this article
Abrahamsen, B. FRAX® in clinical practice. Nat Rev Rheumatol 7, 686–688 (2011). https://doi.org/10.1038/nrrheum.2011.155
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.155
This article is cited by
-
Osteoporosis, frailty and fracture: implications for case finding and therapy
Nature Reviews Rheumatology (2012)
